Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ: ACLX )

30.53 -0.56 (-1.80%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 804,201
Open 31.45
Bid (Size) 27.47 (1)
Ask (Size) 30.51 (5)
Prev. Close 31.09
Today's Range 27.92 - 33.04
52wk Range 6.035 - 35.26
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
What 5 Analyst Ratings Have To Say About Arcellx
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 14, 2023
 
Via Benzinga

Performance

YTD
-1.61%
-1.61%
1 Month
+8.80%
+8.80%
3 Month
-0.29%
-0.29%
6 Month
+52.88%
+52.88%
1 Year
+117.76%
+117.76%

More News

Read More
Benzinga's Top Ratings Upgrades, Downgrades For February 13, 2023
Via Benzinga
Where Arcellx Stands With Analysts
Via Benzinga
Why Is Arcellx (ACLX) Stock Up 25% Today?
Via InvestorPlace
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc. and Arcellx, Inc.
Via Business Wire
20 Favorite Biotech & Medical Stocks For 2023
Via Talk Markets
Dow Tumbles 100 Points; Silver Rises Over 2%
Via Benzinga
US Stocks Turn Higher; Nasdaq Rises 40 Points
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Top-Notch IPO Stock Arcellx Breaks Out On $325 Million Cancer Tie-Up With Gilead Sciences
Via Investor's Business Daily
Why Ambrx Biopharma Shares Are Trading Higher By Over 550%? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
US Stocks Edge Lower; Producer Prices Increase Higher Than Expected
Via Benzinga
Gilead's Kite, Arcellx Ink Over $300M Collaboration Pact For Late-Stage Multiple Myeloma Candidate
Via Benzinga
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 27, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 31, 2022
Via Benzinga
More Than $6 Million Bet On JELD-WEN Holding? 3 Stocks Insiders are Buying
Via Benzinga
Mid-Afternoon Market Update: Dow Dips 900 Points; AC Immune Shares Slide
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Via Benzinga
Mid-Day Market Update: Dow Tumbles 700 points; Advent Technologies Shares Spike Higher
Via Benzinga
63 Biggest Movers From Yesterday
Via Benzinga
37 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.